Bradley Lerman Sells 301 Shares of McKesson (NYSE:MCK) Stock

Posted by Francis Steltz on Aug 13th, 2026

McKesson Corporation (NYSE:MCK – Get Free Report) Director Bradley Lerman sold 301 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $892.33, for a total transaction of $268,591.33. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

McKesson Price Performance

Shares of McKesson stock opened at $877.21 on Thursday. McKesson Corporation has a 1-year low of $659.86 and a 1-year high of $999.00. The stock has a market cap of $102.27 billion, a P/E ratio of 23.47, a P/E/G ratio of 1.77 and a beta of 0.30. The stock’s 50 day simple moving average is $809.56 and its 200-day simple moving average is $842.36.

McKesson (NYSE:MCK – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, topping analysts’ consensus estimates of $9.56 by $0.37. The company had revenue of $105.38 billion for the quarter, compared to analyst estimates of $103.88 billion. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%.The firm’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $8.26 earnings per share. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. As a group, research analysts expect that McKesson Corporation will post 44.65 EPS for the current fiscal year.

McKesson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Tuesday, September 1st will be issued a $0.94 dividend. This is a boost from McKesson’s previous quarterly dividend of $0.82. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Tuesday, September 1st. McKesson’s payout ratio is currently 8.78%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Citigroup increased their price objective on shares of McKesson from $945.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. Barclays lowered their price objective on McKesson from $1,050.00 to $925.00 and set an “overweight” rating for the company in a research report on Wednesday, June 10th. Robert W. Baird set a $1,015.00 target price on McKesson in a report on Thursday, August 6th. William Blair began coverage on shares of McKesson in a report on Tuesday, April 28th. They set an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. cut their target price on McKesson from $1,107.00 to $1,015.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Fourteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $977.00.

Read Our Latest Stock Analysis on MCK

Institutional Investors Weigh In On McKesson

Hedge funds have recently added to or reduced their stakes in the company. Haverford Financial Services Inc. acquired a new stake in shares of McKesson in the 2nd quarter valued at approximately $7,227,000. Benchmark Investment Advisors LLC purchased a new stake in shares of McKesson in the 2nd quarter worth about $441,000. Haverford Trust Co acquired a new stake in shares of McKesson in the second quarter valued at approximately $82,964,000. Clear Harbor Asset Management LLC acquired a new stake in McKesson during the 2nd quarter valued at $4,048,000. Finally, First Nebraska Trust Co purchased a new stake in McKesson during the 2nd quarter worth about $631,000. Institutional investors and hedge funds own 85.07% of the company’s stock.

Key McKesson News

Here are the key news stories impacting McKesson this week:

Positive Sentiment: J.P. Morgan reiterated a Buy rating on McKesson, adding to the bullish analyst support for the stock. McKesson Gets a Buy from J.P. Morgan
Positive Sentiment: Citi maintained its Buy rating, reinforcing confidence in McKesson’s earnings outlook following its latest quarterly report. Citi Keeps Buy Rating on McKesson
Positive Sentiment: McKesson recently exceeded quarterly earnings and revenue expectations, with EPS of $9.93 and revenue of $105.38 billion. Revenue increased 7.7% year over year, while fiscal 2027 EPS guidance remains $44.20–$45.00.
Positive Sentiment: The company raised its quarterly dividend to $0.94 per share from $0.82, signaling confidence in cash generation and shareholder returns.
Neutral Sentiment: Wells Fargo raised its price target to $933 from $812 but retained an Equal Weight rating, suggesting analysts see some additional upside while remaining cautious about valuation. Wells Fargo Raises McKesson Price Target
Negative Sentiment: Director Bradley E. Lerman sold 301 shares worth approximately $268,600. The relatively small transaction may pressure sentiment but does not materially alter McKesson’s fundamentals.
Negative Sentiment: McKesson’s strong rally has brought the stock near its 52-week high, increasing concerns that favorable earnings, analyst targets and growth expectations may already be reflected in the share price.

About McKesson

(Get Free Report)

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.